1
项与 Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School) 相关的临床试验CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on the cell surface of B cells and their precursors. During treatment, patients undergo leukapheresis, lymophodepleting chemotherapy and administration of the expanded CD19-CAR-transduced T cells.
100 项与 Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School) 相关的临床结果
100 项与 Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School) 相关的转化医学
100 项与 Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School) 相关的专利(医药)
100 项与 Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School) 相关的药物交易